Type your tag names separated by a space and hit enter

Homeostatic changes of the endocannabinoid system in Parkinson's disease.

Abstract

Endocannabinoids (eCBs) are endogenous lipids that bind principally type-1 and type-2 cannabinoid (CB(1) and CB(2)) receptors. N-Arachidonoylethanolamine (AEA, anandamide) and 2-arachidonoylglycerol (2-AG) are the best characterized eCBs that are released from membrane phospholipid precursors through multiple biosynthetic pathways. Together with their receptors and metabolic enzymes, eCBs form the so-called "eCB system". The later has been involved in a wide variety of actions, including modulation of basal ganglia function. Consistently, both eCB levels and CB(1) receptor expression are high in several basal ganglia regions, and more specifically in the striatum and in its target projection areas. In these regions, the eCB system establishes a close functional interaction with dopaminergic neurotransmission, supporting a relevant role for eCBs in the control of voluntary movements. Accordingly, compelling experimental and clinical evidence suggests that a profound rearrangement of the eCB system in the basal ganglia follows dopamine depletion, as it occurs in Parkinson's disease (PD). In this article, we provide a brief survey of the evidence that the eCB system changes in both animal models of, and patients suffering from, PD. A striking convergence of findings is observed between both rodent and primate models and PD patients, indicating that the eCB system undergoes dynamic, adaptive changes, aimed at restoring an apparent homeostasis within the basal ganglia network.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neuroscience, University of Rome Tor Vergata, Rome, Italy.

    , , , , ,

    Source

    MeSH

    Animals
    Brain
    Cannabinoid Receptor Modulators
    Endocannabinoids
    Humans
    Parkinson Disease
    Receptors, Cannabinoid

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    21412829

    Citation

    Pisani, Valerio, et al. "Homeostatic Changes of the Endocannabinoid System in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 26, no. 2, 2011, pp. 216-22.
    Pisani V, Madeo G, Tassone A, et al. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord. 2011;26(2):216-22.
    Pisani, V., Madeo, G., Tassone, A., Sciamanna, G., Maccarrone, M., Stanzione, P., & Pisani, A. (2011). Homeostatic changes of the endocannabinoid system in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 26(2), pp. 216-22. doi:10.1002/mds.23457.
    Pisani V, et al. Homeostatic Changes of the Endocannabinoid System in Parkinson's Disease. Mov Disord. 2011 Feb 1;26(2):216-22. PubMed PMID: 21412829.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Homeostatic changes of the endocannabinoid system in Parkinson's disease. AU - Pisani,Valerio, AU - Madeo,Graziella, AU - Tassone,Annalisa, AU - Sciamanna,Giuseppe, AU - Maccarrone,Mauro, AU - Stanzione,Paolo, AU - Pisani,Antonio, Y1 - 2010/12/13/ PY - 2010/06/25/received PY - 2010/08/09/revised PY - 2010/09/03/accepted PY - 2011/3/18/entrez PY - 2011/3/18/pubmed PY - 2011/7/26/medline SP - 216 EP - 22 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 26 IS - 2 N2 - Endocannabinoids (eCBs) are endogenous lipids that bind principally type-1 and type-2 cannabinoid (CB(1) and CB(2)) receptors. N-Arachidonoylethanolamine (AEA, anandamide) and 2-arachidonoylglycerol (2-AG) are the best characterized eCBs that are released from membrane phospholipid precursors through multiple biosynthetic pathways. Together with their receptors and metabolic enzymes, eCBs form the so-called "eCB system". The later has been involved in a wide variety of actions, including modulation of basal ganglia function. Consistently, both eCB levels and CB(1) receptor expression are high in several basal ganglia regions, and more specifically in the striatum and in its target projection areas. In these regions, the eCB system establishes a close functional interaction with dopaminergic neurotransmission, supporting a relevant role for eCBs in the control of voluntary movements. Accordingly, compelling experimental and clinical evidence suggests that a profound rearrangement of the eCB system in the basal ganglia follows dopamine depletion, as it occurs in Parkinson's disease (PD). In this article, we provide a brief survey of the evidence that the eCB system changes in both animal models of, and patients suffering from, PD. A striking convergence of findings is observed between both rodent and primate models and PD patients, indicating that the eCB system undergoes dynamic, adaptive changes, aimed at restoring an apparent homeostasis within the basal ganglia network. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/21412829/abstract/Homeostatic_changes_of_the_endocannabinoid_system_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.23457 DB - PRIME DP - Unbound Medicine ER -